Sat.Dec 28, 2024 - Fri.Jan 03, 2025

article thumbnail

Navigating Virtual Prescribing Policy Changes in 2025

MedCity News

Through collaboration between regulators and healthcare stakeholders, telehealth prescribing can continue to expand treatment access while maintaining proven safety standards. The post Navigating Virtual Prescribing Policy Changes in 2025 appeared first on MedCity News.

Safety 104
article thumbnail

HPLC method demonstrates value for quality control analysis of cardiovascular drug

European Pharmaceutical Review

Researchers have developed a high performance liquid chromatography (HPLC) method that enables accurate determination and precise impurity analysis of the adrenergic -receptor blocker Carvedilol. Carvedilol is commonly used drug to treat cardiovascular diseases , Yuan et al. explained. While there are a variety of methods that can detect and quantify carvedilol, these methods often have limitations in terms of sensitivity, selectivity, or the ability to simultaneously quantify carvedilol and its

article thumbnail

4 companies to watch in the accelerating gene editing race

PharmaVoice

A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.

128
128
article thumbnail

UK regulator warns against buying weight-loss medicines without prescription

PharmaTimes

MHRA urges caution over illegal medicines from beauty salons and social media

Medicine 114
article thumbnail

AI in Marketing & Sales: Today’s Tools, Tomorrow’s Potential

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

article thumbnail

FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions

MedCity News

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions. The post FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions appeared first on MedCity News.

FDA 134
article thumbnail

Early cancer diagnoses reach record level in NHS

pharmaphorum

Early cancer diagnoses have risen to record levels in England, says NHS, but long waiting times for treatment threaten to undermine the gains.

111
111

More Trending

article thumbnail

EC approves Rybrevant with Lazcluze for advanced lung cancer

PharmaTimes

New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC

111
111
article thumbnail

Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data

MedCity News

One Phase 3 test of Auvelity met its main goal in Alzheimers agitation while the drugs other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimers agitation drug. The post Axsome Aims for FDA Filing in Alzheimers Agitation Despite Mixed Bag of Phase 3 Data appeared first on MedCity News.

FDA 113
article thumbnail

Tirzepatide outpacing Wegovy in the obesity space

Pharmaceutical Technology

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

Medical 109
article thumbnail

CARsgen gets a win for CAR-T in solid tumours

pharmaphorum

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.

106
106
article thumbnail

5 Ways You Can Win Faster with Gen AI in Sales

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

article thumbnail

FDA approves Sequana Medical’s Alfapump for ascites treatment

PharmaTimes

FDA gives green light to innovative device for liver conditions

FDA 105
article thumbnail

AI Developers Need Real-World Data — and Atropos Health Is Stepping Up to Help

MedCity News

Many healthcare AI developers lack access to real-world data. To address this, Atropos Health is allowing AI developers to train and deploy their models using its real-world evidence network. The federated healthcare data network consists of more than 300 million patient records gathered from EHRs, claims data and patient registries. The post AI Developers Need Real-World Data and Atropos Health Is Stepping Up to Help appeared first on MedCity News.

article thumbnail

Top 10 Feature Articles of 2024

PharmaTech

The PharmTech Group editors present our most popular technical articles from 2024.

98
article thumbnail

Capricor files cell therapy for DMD cardiomyopathy with FDA

pharmaphorum

Capricor completes its US filing for deramiocel, vying to become the first FDA-approved therapy for cardiomyopathy in Duchenne muscular dystrophy.

FDA 106
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

NHS Confederation welcomes social care commission announcement

PharmaTimes

Government announces independent commission on social care

article thumbnail

5 Notable Health Tech Funding Announcements in December

MedCity News

Health tech companies made several major funding announcements in December. Here is a list of some of the biggest funding rounds. The post 5 Notable Health Tech Funding Announcements in December appeared first on MedCity News.

116
116
article thumbnail

Navigating Access and Reimbursement Through Uncertainty

Pharmaceutical Commerce

A forum intended for HCPs, policy experts, and industry leaders addresses pressing obstacles facing this sector of the industry today.

85
article thumbnail

Roche licenses Innovent ADC that could challenge Amgen drug

pharmaphorum

Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market

Marketing 106
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

The year ahead for RNA therapeutic development and manufacturing

European Pharmaceutical Review

The RNA therapeutics industry stands poised for a transformative 2025, driven by breakthroughs in technology, expanding clinical applications, and a rapidly growing pipeline of innovative therapies. Following the unprecedented speed and success of mRNA-based COVID-19 vaccine development, the field has experienced a surge in investment and research to unlock the powerful potential of RNA for other therapeutic applications.

article thumbnail

Healthcare IT in 2025: Triage for the Age of AI

MedCity News

Amid the chaos and confusion of healthcare IT in our age of AI, a triage concept may be the best guide for organizations fighting to stray strong and capable in 2025 and beyond. The post Healthcare IT in 2025: Triage for the Age of AI appeared first on MedCity News.

article thumbnail

FDA Releases Draft Guidance on Sampling and Testing of In-Process Materials and Drug Products

PharmaTech

The draft guidance document provides recommendations for complying with 21 CFR 211.110.

FDA 69
article thumbnail

Flagship-backed AI startup Valo shelves eye disease drug

pharmaphorum

Valo Health will no longer develop its ROCK1/2 inhibitor for diabetic retinopathy on its own after a trial readout but will seek to partner the drug

105
105
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

NICE makes first-of-a-kind recommendation for hearing loss drug

European Pharmaceutical Review

The National Institute for Health and Care Excellence (NICE) has recommended the first drug for NHS use to prevent cisplatin-induced hearing loss ( ototoxicity ) in children and young people between the ages of one month and 17 years old.Pedmarqsi (anhydrous sodium thiosulfate) is indicated for these children who have localised, non-metastatic, solid tumours.

article thumbnail

Top Priorities and Challenges for Digital Health Leaders in 2025: 5 Key Insights

MedCity News

About 79% of digital health leaders said their companies are pursuing new investment capital in the next year, according to a recent survey from Summit Health Advisors. The post Top Priorities and Challenges for Digital Health Leaders in 2025: 5 Key Insights appeared first on MedCity News.

112
112
article thumbnail

FDA Publishes Final Guidance on Advanced Manufacturing Technologies

PharmaTech

The guidance provides recommendations for those interested in participating in FDAs Advanced Manufacturing Technologies Designation Program.

article thumbnail

Pfizer ducks out of Sangamo haemophilia A alliance

pharmaphorum

Sangamo is 'surprised and disappointed' by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results

106
106
article thumbnail

10 Ways to Leverage Buyer Signals and Drive Revenue

In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.

article thumbnail

Mastering Pharmaceutical Marketing: Strategies to Drive Success in the Pharma Industry

Pharma Marketing Network

Table of Contents Sr# Headings 1 Introduction: The Pharma Marketing Challenge 2 Building a Winning Pharma Marketing Strategy 3 The Role of Branded Drug Campaigns 4 Innovating for Future Success Introduction: The Pharma Marketing Challenge Marketing pharmaceuticals is no small feat. In an industry where lives are at stake, creating compelling, compliant, and effective campaigns can feel like walking a tightrope.

article thumbnail

Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing

MedCity News

Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program. The post Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing appeared first on MedCity News.

FDA 120
article thumbnail

Top 10 Video Interviews of 2024

PharmaTech

The PharmTech Group editors present our most popular interviews from 2024.

69
article thumbnail

Neumora laid low by depression trial failure

pharmaphorum

The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price

105
105
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten